Special Issue

Movement Disorders and Therapeutic Applications of Botulinum Toxin

Message from the Guest Editors

Movement disorders were among the earliest therapeutic uses of botulinum toxin. The use of BoNT for neurosecretory disorders has expanded, including the treatment of sialorrhea which is often seen in association with a movement disorder. A number of these conditions lack other effective treatments, making botulinum toxin a first-line therapy. The number of applications continues to evolve along with increasing understanding of botulinum toxin's physiologic effects centrally and peripherally and its mechanism of action in treating movement disorders. The methodology of administering botulinum toxin is similarly progressing. This Special Issue will focus on the current status of botulinum toxin for the treatment of movement disorders (encompassing focal, generalized and secondary dystonias, tremor, ataxia, tics, and chorea), sialorrhea, as well as technical approaches to botulinum toxin usage, including issues such as dosing, guidance techniques, and target muscle selection.

Guest Editors

Dr. Barbara Karp

Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA

Dr. Katharine Alter

Department of Rehabilitation Medicine, National Institutes of Health, Bethesda, MD 20892, USA

Deadline for manuscript submissions

closed (31 December 2020)

Toxins

an Open Access Journal by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed

mdpi.com/si/41343

Toxins
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
toxins@mdpi.com

mdpi.com/journal/toxins

Toxins

an Open Access Journal by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed

mdpi.com/journal/toxins

About the Journal

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Editor-in-Chief

Prof. Dr. Jay Fox
Department of Microbiology, University of Virginia, Charlottesville, VA, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.4 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI